Mirati Therapeu…
ProfileJobs

Mirati Therapeutics

Suggest Edit
    • Healthbiotechdrug developmentoncologypharma

    Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

    Market capitalization(2018-04-18)
    $770.1 M
    Type
    Public
    HQ
    San Diego, US
    Founded
    2013
    Size (employees)
    38 (est)
    Website
    mirati.com
    Mirati Therapeutics was founded in 2013 and is headquartered in San Diego, US
    Report incorrect company information

    Mirati Therapeutics Office Locations

    Mirati Therapeutics has an office in San Diego
    San Diego, US (HQ)
    200 9393 Towne Centre Dr
    Show all (1)
    Report incorrect company information

    Mirati Therapeutics Financials and Metrics

    Mirati Therapeutics Financials

    USD

    Net income (FY, 2017)

    		(70.4 m)

    EBIT (FY, 2017)

    		(71.5 m)

    Market capitalization (18-Apr-2018)

    		770.1 m

    Cash (31-Dec-2017)

    		107.7 m
    Mirati Therapeutics's current market capitalization is $770.1 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    General and administrative expense

    		15.3 m13.5 m

    R&D expense

    		68.5 m58.1 m

    Operating expense total

    		83.8 m71.5 m

    EBIT

    		(32 m)(39.1 m)(64.7 m)(83.8 m)(71.5 m)
    Quarterly
    USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    General and administrative expense

    		2.4 m2.9 m3.5 m3.8 m4.2 m4.2 m4.1 m3.8 m3.5 m3.7 m3.7 m

    R&D expense

    		5.2 m7.2 m7 m8.2 m11.3 m14.6 m18 m18.4 m16.1 m14.4 m15 m

    Operating expense total

    		8 m10.1 m10.5 m12 m15.5 m18.7 m22.1 m22.2 m19.6 m18.1 m18.6 m

    EBIT

    		(8 m)(10.1 m)(10.5 m)(12 m)(15.5 m)(18.7 m)(22.1 m)(22.2 m)(19.6 m)(18.1 m)(18.6 m)
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		14.2 m6.6 m49.5 m22.4 m107.7 m

    Accounts Receivable

    Inventories

    Current Assets

    		64.2 m32.7 m125.4 m59.6 m155.8 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    Cash

    		7.6 m8.3 m8.5 m4.9 m14.3 m13.4 m109.9 m34.6 m24.5 m19.8 m29.8 m20 m

    Current Assets

    		17 m56 m49.2 m40.3 m71.2 m60.9 m141 m109.9 m93 m75.5 m107.9 m92.3 m

    PP&E

    		427 k275 k479 k524 k667 k693 k639 k601 k558 k537 k638 k618 k

    Total Assets

    		18 m56.3 m49.7 m41.3 m72.2 m61.9 m143.7 m112.5 m96 m79.2 m110.8 m95 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(43.7 m)(64.5 m)(83.1 m)(70.4 m)

    Depreciation and Amortization

    		171 k199 k212 k180 k184 k

    Inventories

    Accounts Payable

    		(1.3 m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    		(13.7 m)(11 m)(8.6 m)(11.9 m)(15.4 m)(18.7 m)(21.9 m)(22.1 m)(19.4 m)(17.8 m)

    Depreciation and Amortization

    		105 k

    Purchases of PP&E

    		(199 k)
    show all
    USDY, 2017

    Financial Leverage

    		1.1 x
    Show all financial metrics

    Mirati Therapeutics Operating Metrics

    FY, 2016

    Patents Issued

    		32

    Patents Pending

    		1
    Show all operating metrics
    Report incorrect company information

    Competitors

    Juniper Pharmaceuticals
    Health - Public
    Innoviva
    Health - Public
    Oxis International
    Health - Public
    Inovio Pharmaceuticals
    Health - Public
    Compare competitors
    Download PDF